Nuo Therapeutics secures up to $1.6M loan with 10%-12% PIK interest paid in warrants; insider participation

Nuo Therapeutics, Inc.

Loan agreement for $1.0M initial + $600K second tranche (Sept 30, 2026); $1.0M funded Jan 23, 2026.
Interest 10% annual on initial note, rising to 12% if second tranche is taken; accrued interest paid only in warrants at maturity.
Principal repaid in 8 equal quarterly installments from Mar 31, 2027 to Dec 31, 2028; early prepayment fee 1.5-2.75% of principal paid in warrants.
Lenders include director/10% owner Scott Pittman ($200K) and >5% owner Paul Jacobs ($300K); each received initial and potential second warrants.
Warrants exercisable at $1.50/share, expiring Jan 23, 2031; up to 226,000 interest warrant shares issuable at maximum borrowing.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Nuo Therapeutics, Inc. incurred credit facility of aggregate principal amount of up to $1.6 million with four lenders (including Scott M. Pittman and Paul Anthony Jacobs) at annual rate of 10% maturing December 31, 2028.

Instrument: credit facility
Principal: aggregate principal amount of up to $1.6 million
Counterparty: four lenders (including Scott M. Pittman and Paul Anthony Jacobs)
Rate: annual rate of 10%
Maturity: December 31, 2028
Event: incurrence

Exact text from the filing

On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million with (a) $1.0 million funded on the initial closing date (the “Initial Funding”) and (b) $600 thousand to be funded, if requested in advance by the Company and subject to closing conditions, on September 30, 2026 (the “Second Funding”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Nuo Therapeutics, Inc. entered into Loan and Security Agreement with four lenders (collectively, the "Lenders") valued at up to $1.6 million (effective 2026-01-21).

Action: entry
Agreement: credit facility
Counterparty: four lenders (collectively, the "Lenders")
Value: up to $1.6 million
Effective: 2026-01-21

Exact text from the filing

On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million

View on SEC.gov

306 debt financings filed in the last 30 days. Browse all debt financings →

Nuo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-002078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.